Ten Years of Treatment With Tacrolimus Is Related to an Excellent Renal Function, Allowing Monotherapy in a Large Proportion of Cases: Unicentric Results of the Tacrolimus Versus Cyclosporine A European Multicentric Study in Kidney Transplant Patients

Transplantation Proceedings(2005)

引用 14|浏览6
暂无评分
摘要
Tacrolimus (Tac) is the most frequently used base inmunosuppressant for transplantation in Spain and the United States. However, long-term data on its use in renal transplant patients are lacking. The aim of this study was to analyze the 10-year outcome of patients from our institution treated with Tac or cyclosporine (CsA) who were included in the European Multicenter Study of kidney transplantation (1993 to 1994). This trial compared the efficacy and safety of steroids + Tac + azathioprine versus steroids + CsA + azathioprine at 1 year, showing a significantly lower acute rejection rate in Tac patients, with no differences in graft or patient survival. In our long-term analysis, we included patients with a functioning graft after the first year: 15 patients on Tac and 11 on CsA. In the “intent-to-treat” (ITT) analysis, patient survival was 14/15 (93%) versus 9/11 (82%) and death noncensored graft survival was 10/15 (67%) versus 8/11 (73%) in Tac and CsA, respectively. Analyzing patients “into treatment” (TT), death/noncensored graft survival was 11/16 (69%) versus 6/9 (67%), respectively.
更多
查看译文
关键词
glucose metabolism,systolic blood pressure,creatinine clearance,kidney function,intent to treat,renal function,blood pressure
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要